Viral Vector– tag –
-
Asahi Kasei Bioprocess Launches VANTIJ® SU-VFC Benchtop to Elevate Efficiency and Consistency in Gene Therapy Manufacturing
Asahi Kasei Japan Overview Asahi Kasei Bioprocess has introduced the VANTIJ® SU-VFC Benchtop, a novel small-format, automated, single-use virus filtration system for gene therapy manufacturing. This system is designed to significantly en... -
Northway Biotech Unveils €61M Personalized Medicine & CAR-T Manufacturing Plant in Lithuania, Accelerating European CGT Hub Formation
European Biotechnology Lithuania Overview CDMO Northway Biotech has invested €61 million to open a state-of-the-art cell therapy and personalized medicine center in Vilnius, Lithuania. The facility is actively pursuing GMP manufacturing ... -
Tempest Therapeutics Licenses Senlang’s In Vivo CAR-T Platform, Targeting Relapsed/Refractory Multiple Myeloma with Dual BCMA/GPRC5D Approach in Phase I Trial
AllSci USA Overview Tempest Therapeutics has secured an exclusive license option for Hebei Senlang Biotechnology's CD7-targeting lentiviral in vivo CAR-T platform and related product candidates. This platform generates CAR-T and CAR-NK c... -
Beam Therapeutics Pursues Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency, Citing Positive Phase 1/2 Clinical Data
Simply Wall St USA Overview Beam Therapeutics announced updated Phase 1/2 clinical trial data for BEAM-302, its treatment for Alpha-1 Antitrypsin Deficiency (AATD), showing an acceptable safety profile and promising biomarker data indica... -
CRISPR Therapeutics Anticipates CASGEVY Market Expansion and Key Pipeline Catalysts by Year-End 2026
MarketBeat USA Overview CRISPR Therapeutics expresses strong optimism for the continued market adoption of its approved gene-editing therapy, CASGEVY, and anticipates significant data updates from multiple key pipeline programs by the en... -
CRISPR Therapeutics Forges Long-Term Growth with In Vivo Editing and Gene Insertion Following CASGEVY Approval
The Motley Fool USA Overview CRISPR Therapeutics reportedly aims for significant growth over the next decade by building on the commercialization of its approved sickle cell disease and transfusion-dependent beta-thalassemia therapy, CAS... -
Australia Establishes Sovereign Viral Vector Manufacturing with VVMF TGA License, Boosting Asia-Pacific Cell & Gene Therapy Capabilities
TechNode Global Australia Overview Australia's Viral Vector Manufacturing Facility (VVMF) has secured a Therapeutic Goods Administration (TGA) manufacturing license for its Sydney site. This enables VVMF to produce GMP-compliant viral ve... -
In Vivo CAR T-cell Generation Advances: VivoVec Platform Streamlines Manufacturing and Treatment Workflows, Reducing Lymphodepletion Dependence
Frontiers International Overview Advances in in vivo CAR T-cell generation, particularly platforms like VivoVec, show potential to simplify manufacturing and treatment workflows by enhancing CAR T-cell expansion and persistence. This app... -
Australia’s VVMF Sydney Facility Secures TGA GMP License for Gene and Cell Therapy Manufacturing, Bolstering Domestic CDMO Capacity
Contract Pharma USA Overview Australia's Viral Vector Manufacturing Facility (VVMF) has officially received a Therapeutic Goods Administration (TGA) GMP license for therapeutic product manufacturing at its Sydney site, effective Septembe... -
Drug Discovery News Highlights Rising Complexity in Biologics Manufacturing: Urges Manufacturability by Design, Raw Material Quality, and Process Intensification
Drug Discovery News USA Overview Drug Discovery News reports on the increasing complexity in manufacturing biologics, cell-based therapies (including CAR T), viral vectors, and oligonucleotides. The article identifies key challenges such...
